Disclosed are pharmaceutical combination products useful for the treatment of Parkinson's disease. These products are based on a combination of active ingredients which are carbidopa, levodopa, and deprenyl in a pharmaceutical carrier, preferably a carrier wherein one or more of the active ingredients are in a sustained release oral dosage formulation.
Deprenyl/L-dopa/carbidopa pharmaceutical composition.